three classes of genes over the following two decades. Roeder continued to identify a number of important sequence-specific transcription factors and co-activator/mediator complexes.
Gene transcription is a key downstream target for most signalling pathways and is one of the central ways in which the expression of gene products is regulated. In addition, transcriptional regulation is integrated with DNA repair, cell cycle checkpoints and chromatin remodelling. The precise spatio-temporal regulation of specific genes underlies most physiological responses, such as development, cell growth and differentiation, and the immune response, as so strikingly demonstrated these days by microarray data and in situ hybridization. Almost every process derailed in cancer ultimately leads to altered gene expression profiles. As a result, it is maybe not surprising that the complexity of the eukaryotic transcriptional apparatus has grown so dramatically in several waves of discovery (RNA polymerases, basal transcription factors, specific transcription factors, coactivators/repressors and chromatin remodelling factors) to form the highly regulatable and specific multisubunit machines we appreciate today.
The clinical research award highlights a classic, and still all too rare, bench-to-bedside success: Marc Feldmann and Ravinder Maini of the Imperial College School of Medicine (London) are honoured for establishing anti-tumour necrosis factor (TNF)-α therapy as an effective treatment for autoimmune diseases such as rheumatoid arthritis and Crohn disease, with three licensed drugs currently available. This long-term collaboration between the basic immunologist Feldmann and the clinical rheumatologist Maini saw them delineate the TNF cascade of inflammatory cytokines in rheumatism, test antibody inhibition of TNF in animal models and translate the concept into the clinic. As such, this highly successful collaboration should inspire as a paradigm for mining the considerable clinical potential of basic cell biology.
